Effect of a new CCK-A receptor antagonist, dexloxiglumide, on the exocrine pancreas in the rat

G. Varga, K. Kisfalvi, M. D'Amato, C. Scarpignato

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The effect of dexloxiglumide, a new potent cholecystokinin (CCK) antagonist, on pancreatic enzyme secretion and growth was studied in the rat. Pancreatic exocrine secretion was studied both in vitro (isolated and perfused pancreatic segments) and in vivo (anesthetized animals with cannulation of the common bile duct) whereas the trophic effect was investigated after short-term (7 days) administration of the CCK-agonist, caerulein, or camostate (a potent trypsin inhibitor), with or without dexloxiglumide. CCK-8 stimulated amylase release from in vitro pancreatic segments in a concentration-dependent manner. Dexloxiglumide displaced the concentration reponse curves to CCK-8 to the right without affecting the maximum response, suggesting a competitive antagonism. The Schild plot analysis of data gave a straight line with a slope (0.90 ± 0.36) not significantly different from unity. The calculated pA2 for dexloxiglumide was 6.41 ± 0.38. In vitro experiments confirmed results from in vitro studies since intravenous dexloxiglumide reduced pancreatic exocrine secretion induced by submaximal CCK-8 stimulation (0.5 nmol/kg/h) in a dose-dependent manner, the ID50 being 0.64 mg/kg. Both exogenous and endogenous (released by camostate) CCK increased the weight of the pancreas, the total pancreatic protein and DNA, trypsin and amylase content. Dexloxiglumide (25 mg/kg), administered together with caerulein (1 μg/kg), reduced the peptide-induced increase in pancreatic weight, protein and enzyme content. Similarly, when dexloxiglumide was given together with camostate (200 mg/kg), all the observed changes were reduced by concomitant administration of the antagonist. These results demonstrate the ability of dexloxiglumide to antagonize the effects of CCK on pancreatic secretion and growth, suggesting that this compound is a potent and selective antagonist of CCK-A-receptors in the pancreas.

Original languageEnglish
Pages (from-to)257-264
Number of pages8
JournalJournal of Physiology Paris
Volume91
Issue number3-5
DOIs
Publication statusPublished - May 1997

Fingerprint

Cholecystokinin A Receptor
Exocrine Pancreas
Cholecystokinin
Ceruletide
Amylases
Pancreas
Weights and Measures
Trypsin Inhibitors
dexloxiglumide
Common Bile Duct
Enzymes
Growth
Catheterization
Trypsin
Proteins
Peptides

Keywords

  • Antagonist
  • Cholecystokinin
  • Pancreas
  • Receptor

ASJC Scopus subject areas

  • Neuroscience(all)
  • Physiology (medical)

Cite this

Effect of a new CCK-A receptor antagonist, dexloxiglumide, on the exocrine pancreas in the rat. / Varga, G.; Kisfalvi, K.; D'Amato, M.; Scarpignato, C.

In: Journal of Physiology Paris, Vol. 91, No. 3-5, 05.1997, p. 257-264.

Research output: Contribution to journalArticle

Varga, G. ; Kisfalvi, K. ; D'Amato, M. ; Scarpignato, C. / Effect of a new CCK-A receptor antagonist, dexloxiglumide, on the exocrine pancreas in the rat. In: Journal of Physiology Paris. 1997 ; Vol. 91, No. 3-5. pp. 257-264.
@article{28a0c77bc74d4ab48d98bc1925894e0a,
title = "Effect of a new CCK-A receptor antagonist, dexloxiglumide, on the exocrine pancreas in the rat",
abstract = "The effect of dexloxiglumide, a new potent cholecystokinin (CCK) antagonist, on pancreatic enzyme secretion and growth was studied in the rat. Pancreatic exocrine secretion was studied both in vitro (isolated and perfused pancreatic segments) and in vivo (anesthetized animals with cannulation of the common bile duct) whereas the trophic effect was investigated after short-term (7 days) administration of the CCK-agonist, caerulein, or camostate (a potent trypsin inhibitor), with or without dexloxiglumide. CCK-8 stimulated amylase release from in vitro pancreatic segments in a concentration-dependent manner. Dexloxiglumide displaced the concentration reponse curves to CCK-8 to the right without affecting the maximum response, suggesting a competitive antagonism. The Schild plot analysis of data gave a straight line with a slope (0.90 ± 0.36) not significantly different from unity. The calculated pA2 for dexloxiglumide was 6.41 ± 0.38. In vitro experiments confirmed results from in vitro studies since intravenous dexloxiglumide reduced pancreatic exocrine secretion induced by submaximal CCK-8 stimulation (0.5 nmol/kg/h) in a dose-dependent manner, the ID50 being 0.64 mg/kg. Both exogenous and endogenous (released by camostate) CCK increased the weight of the pancreas, the total pancreatic protein and DNA, trypsin and amylase content. Dexloxiglumide (25 mg/kg), administered together with caerulein (1 μg/kg), reduced the peptide-induced increase in pancreatic weight, protein and enzyme content. Similarly, when dexloxiglumide was given together with camostate (200 mg/kg), all the observed changes were reduced by concomitant administration of the antagonist. These results demonstrate the ability of dexloxiglumide to antagonize the effects of CCK on pancreatic secretion and growth, suggesting that this compound is a potent and selective antagonist of CCK-A-receptors in the pancreas.",
keywords = "Antagonist, Cholecystokinin, Pancreas, Receptor",
author = "G. Varga and K. Kisfalvi and M. D'Amato and C. Scarpignato",
year = "1997",
month = "5",
doi = "10.1016/S0928-4257(97)89494-6",
language = "English",
volume = "91",
pages = "257--264",
journal = "Journal de Physiologie",
issn = "0928-4257",
publisher = "Elsevier Masson SAS",
number = "3-5",

}

TY - JOUR

T1 - Effect of a new CCK-A receptor antagonist, dexloxiglumide, on the exocrine pancreas in the rat

AU - Varga, G.

AU - Kisfalvi, K.

AU - D'Amato, M.

AU - Scarpignato, C.

PY - 1997/5

Y1 - 1997/5

N2 - The effect of dexloxiglumide, a new potent cholecystokinin (CCK) antagonist, on pancreatic enzyme secretion and growth was studied in the rat. Pancreatic exocrine secretion was studied both in vitro (isolated and perfused pancreatic segments) and in vivo (anesthetized animals with cannulation of the common bile duct) whereas the trophic effect was investigated after short-term (7 days) administration of the CCK-agonist, caerulein, or camostate (a potent trypsin inhibitor), with or without dexloxiglumide. CCK-8 stimulated amylase release from in vitro pancreatic segments in a concentration-dependent manner. Dexloxiglumide displaced the concentration reponse curves to CCK-8 to the right without affecting the maximum response, suggesting a competitive antagonism. The Schild plot analysis of data gave a straight line with a slope (0.90 ± 0.36) not significantly different from unity. The calculated pA2 for dexloxiglumide was 6.41 ± 0.38. In vitro experiments confirmed results from in vitro studies since intravenous dexloxiglumide reduced pancreatic exocrine secretion induced by submaximal CCK-8 stimulation (0.5 nmol/kg/h) in a dose-dependent manner, the ID50 being 0.64 mg/kg. Both exogenous and endogenous (released by camostate) CCK increased the weight of the pancreas, the total pancreatic protein and DNA, trypsin and amylase content. Dexloxiglumide (25 mg/kg), administered together with caerulein (1 μg/kg), reduced the peptide-induced increase in pancreatic weight, protein and enzyme content. Similarly, when dexloxiglumide was given together with camostate (200 mg/kg), all the observed changes were reduced by concomitant administration of the antagonist. These results demonstrate the ability of dexloxiglumide to antagonize the effects of CCK on pancreatic secretion and growth, suggesting that this compound is a potent and selective antagonist of CCK-A-receptors in the pancreas.

AB - The effect of dexloxiglumide, a new potent cholecystokinin (CCK) antagonist, on pancreatic enzyme secretion and growth was studied in the rat. Pancreatic exocrine secretion was studied both in vitro (isolated and perfused pancreatic segments) and in vivo (anesthetized animals with cannulation of the common bile duct) whereas the trophic effect was investigated after short-term (7 days) administration of the CCK-agonist, caerulein, or camostate (a potent trypsin inhibitor), with or without dexloxiglumide. CCK-8 stimulated amylase release from in vitro pancreatic segments in a concentration-dependent manner. Dexloxiglumide displaced the concentration reponse curves to CCK-8 to the right without affecting the maximum response, suggesting a competitive antagonism. The Schild plot analysis of data gave a straight line with a slope (0.90 ± 0.36) not significantly different from unity. The calculated pA2 for dexloxiglumide was 6.41 ± 0.38. In vitro experiments confirmed results from in vitro studies since intravenous dexloxiglumide reduced pancreatic exocrine secretion induced by submaximal CCK-8 stimulation (0.5 nmol/kg/h) in a dose-dependent manner, the ID50 being 0.64 mg/kg. Both exogenous and endogenous (released by camostate) CCK increased the weight of the pancreas, the total pancreatic protein and DNA, trypsin and amylase content. Dexloxiglumide (25 mg/kg), administered together with caerulein (1 μg/kg), reduced the peptide-induced increase in pancreatic weight, protein and enzyme content. Similarly, when dexloxiglumide was given together with camostate (200 mg/kg), all the observed changes were reduced by concomitant administration of the antagonist. These results demonstrate the ability of dexloxiglumide to antagonize the effects of CCK on pancreatic secretion and growth, suggesting that this compound is a potent and selective antagonist of CCK-A-receptors in the pancreas.

KW - Antagonist

KW - Cholecystokinin

KW - Pancreas

KW - Receptor

UR - http://www.scopus.com/inward/record.url?scp=0030670843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030670843&partnerID=8YFLogxK

U2 - 10.1016/S0928-4257(97)89494-6

DO - 10.1016/S0928-4257(97)89494-6

M3 - Article

C2 - 9403804

AN - SCOPUS:0030670843

VL - 91

SP - 257

EP - 264

JO - Journal de Physiologie

JF - Journal de Physiologie

SN - 0928-4257

IS - 3-5

ER -